Thiogenesis Therapeutics Corp.

Stock factsheet

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Based in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a patented new chemical entity designed to deliver sustained cysteamine exposure through proprietary prodrug chemistry rather than conventional controlled-release formulation technology. This differentiated approach is intended to improve tolerability, convenience and therapeutic exposure relative to existing cysteamine therapies. The Company's lead program is in nephropathic cystinosis, where TTI-0102 is advancing toward late-stage clinical development. Thiogenesis is also developing TTI-0102 for primary mitochondrial diseases, including Leigh syndrome spectrum, and is preparing to initiate a Phase 2 clinical trial.

Company description as published by the issuer via TMX Money.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

Investor Relations

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.